Colorectal Cancer
Conditions
Interventions
None listed
Sponsors
Department of Gastroenterology and Hepatology, Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients of colorectal cancer who were treated with FTD/TPI or Regorafenib.(Patients who received both FTD/TPI and regorafenib in the same case and met other inclusion/exclusion criteria should be enrolled for each treatment.) 2)Patients who have been tested for CA125 within 28 days prior to the start of the above treatment. 3)Age <=20 years old at the time of diagnosis. 4)patients who have not rejected the participation of this study from the research subjects or their agent(person who is thought to be able to speak for the will and interest of the research subject).
Exclusion criteria
Exclusion criteria: 1)Participation in the clinical trial is determined as unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, Response rate, Disease control rate, Search for treatment effect predictor and prognostic predictors, treatment effect on ascites | — |
Countries
Japan
Contacts
Public ContactKen Ito
Hokkaido University Hospital Cancer Center
Outcome results
None listed